Sana Biotechnology

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that five abstracts will have poster presentations at the 65th American Society of Hematology Annual Meeting to be held December 9-12, 2023 in San Diego, CA.

Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting

Sana Biotechnology will reduce its workforce by 29%, the Seattle-based cell and gene therapy company revealed in a SEC filing Tuesday.

Sana Biotechnology will lay off 29% of workforce

Increasing focus on ex vivo cell therapy platform based on extensive preclinical and early translational clinical data suggesting ability of hypoimmune (HIP)-modified cells to evade immune detection

Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M

Denali Therapeutics

Foghorn Therapeutics

Seres Therapeutics

Moderna

Omega Therapeutics

CAMBRIDGE, Mass. , Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer.

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at five investor conferences in September. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer, and Nate Hardy, Sana's Chief Financial Officer.

Sana Biotechnology to Present at September 2023 Investor Conferences

Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial data expected this year

Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates

Results from the phase 1 study using SC291 for the treatment of patients with B-cell lymphomas are expected to be released later in 2023. It is said that the global B-cell lymphoma treatment market could reach $13.14 billion by 2030. The company is testing the use of its hypoimmune platform, which might be capable of providing long-term durable responses, without immunosuppression being needed.

Sana Biotechnology: Hypoimmune Platform Might Stealth Cells

Empress's Chemilogics™ product platform creates small molecule drugs quickly and cost-effectively The company emerges after two years of platform development with an initial commitment of $50 million from Flagship Pioneering Empress has identified and characterized 15 potential small molecule drugs in less than two years; it expects to file multiple Investigational New Drug (IND) applications within the next 24 months Murray McKinnon, Ph.D., former Global Head of J&J's World Without Disease Accelerator and Head of Immunology Discovery within Janssen Pharmaceuticals, appointed Chief Scientific Officer CAMBRIDGE, Mass.

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

Hypoimmune (HIP)-modified CD19-directed CAR T cells have the potential to serve as a universal off-the-shelf therapy that provides long-term durability of response without immunosuppression

Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting

SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

Sana Biotechnology to Present at June 2023 Investor Conferences

Hypoimmune-modified allogeneic iPSCs evade immune response and rejection without immunosuppression in non-human primate model

Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional

IND cleared and enrolling patients in SC291 Phase 1 clinical trial in B-cell malignancies with initial data expected later this year

Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

Cue Biopharma

Precigen

Ardelyx

Atossa Genetics

Bioline RX

Corvus Pharmaceuticals

Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.

7 High-Potential Penny Stocks in the Biotech Sector

SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in May. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer and Nate Hardy, Sana's Chief Financial Officer.

Sana Biotechnology to Present at May 2023 Investor Conferences

The average of price targets set by Wall Street analysts indicates a potential upside of 83.2% in Sana (SANA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Sana (SANA) Could Rally 83.17%: Here's is How to Trade

SEATTLE, May 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that six abstracts highlighting preclinical data from the fusogen platform have been accepted for presentation, including two oral presentations, at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting taking place May 16-20, 2023 in Los Angeles, CA.

Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

SEATTLE, April 24, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that management will host a Research & Development (R&D) Day on Thursday, May 23, 2023 from 9:00 a.m. – 12:00 p.m. ET in New York, NY.

Sana Biotechnology to Host Research & Development Day

Axsome Therapeutics

CRISPR Therapeutics

Investors may want to keep an eye on the biotech boom and these top biotech stocks to watch. For one, the sector is still one of the safest, most recession-proof investments around.

The Top 3 Biotech Stocks to Watch in 2023

Hypoimmune-modified CD19-directed CAR T cells persist and remain functional in preclinical models over multiple months in an allogeneic humanized immune system, even with tumor re-challenge

Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting

The average of price targets set by Wall Street analysts indicates a potential upside of 78.2% in Sana (SANA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Sana (SANA) Have the Potential to Rally 78.23% as Wall Street Analysts Expect?

Sana Biotechnology Is Technically Overbought So Buy It Later

Brookdale Senior Living

The week that ended April 14 was a good one for markets overall and a great one for two stocks in the healthcare sector. Sana Biotechnology jumped 58% higher last week as investors cheered preclinical results for its lead candidates.

2 Growth Stocks That Jumped 42% and 58% Last Week: Can They Still Climb Higher?

Sana Biotechnology is developing a cell-editing platform that it hopes will be able to avoid immune-system rejection. The company has no revenue but enough cash to fund operations into 2025, it said.

Why Shares of Sana Biotechnology Jumped This Week

Hypoimmune-modified allogeneic CD19-directed CAR T cells can evade immune detection and kill tumor cells in a novel humanized allogeneic preclinical model in vivo, including following tumor cell reinjection

Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses

Hypoimmune human islet cells normalized glucose in diabetic humanized immunocompetent mouse model and avoided allogeneic and autoimmune rejection by the immune system

Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model

News for Sana Biotechnology Stock (SANA)